- $13.72m
- $40.07m
- $3.00m
Annual income statement for PAVmed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.5 | 0.377 | 2.45 | 3 |
| Cost of Revenue | |||||
| Gross Profit | — | -0.085 | -3.24 | -3.97 | -1.84 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 29.8 | 58.3 | 96.7 | 75 | -20.3 |
| Operating Profit | -29.8 | -57.8 | -96.4 | -72.6 | 23.3 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -35.9 | -56.1 | -103 | -79.3 | 28.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -35.9 | -56.1 | -103 | -79.3 | 28.4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -34.3 | -50.3 | -89 | -64.2 | 39.8 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -34.6 | -50.6 | -89.3 | -66.3 | 32.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -8.88 | -9.14 | -14.1 | -8.78 | -0.542 |